CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Netherlands' Qiagen Q3 sales, adjusted EPS top outlook; suspends 2026 guidance

By Reuters News


Overview

  • Netherlands molecular diagnostics firm's Q3 net sales rose 3% yr/yr, exceeding company outlook

  • Adjusted diluted EPS for Q3 rose to $0.65, above company outlook

  • Company suspended 2026 financial guidance due to pending EQT Private Equity transaction


Outlook

  • Qiagen has suspended its 2026 outlook due to the pending EQT Private Equity transaction


Result Drivers

  • CONSUMABLES GROWTH - Consumables and related revenues rose 3% CER and made up 91% of sales, while instrument sales rose 1% CER

  • MARGIN IMPROVEMENT - Higher-margin consumables and efficiency gains contributed to increased adjusted operating income margin

  • GROWTH PILLARS - Sales from QIAGEN's growth pillars rose 7% CER to $415 mln, partly offset by a 7% CER decline in the rest of the portfolio


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 EPS

$0.51

Q3 Adjusted Operating Income Margin

30.40%


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for QIAGEN N.V. is €44.61, about 1.4% below its November 4 closing price of €45.23

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Nov 3 - Netherlands' Philips slightly misses Q3 revenue estimates, maintains 2026 forecast

  • Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.